Onyema Ogbuagu, MBBCh, FACP, FIDSA discussed 96% virologic suppression with lenacapavir-based therapy, showing similar results to daily oral regimens.
Onyema Ogbuagu, MBBCH, FACP, FIDSA
Advertisement
Ogbuagu is an associate professor of medicine and director of the HIV clinical trials program of the Yale AIDS Program, section of infectious diseases at the Yale School of Medicine in New Haven, Connecticut.
Articles by Onyema Ogbuagu, MBBCH, FACP, FIDSA
Findings from the CAPELLA study reveal virologic suppression and a safety profile for multidrug-resistant HIV-1.
Gilead’s HIV-1 capsid inhibitor, which is a twice-yearly injection, was more effective than a daily Truvada pill in a phase 3 trial.
The therapy, lenacapavir, showed sustained virological suppression and safety over a 2-year period in this treatment-challenged patient population.
Advertisement
Latest Updated Articles
Long-Acting Lenacapavir Shows Efficacy in Heavily Treatment-Experienced PatientsPublished: November 11th 2024 | Updated:
Examining a Newer Therapy for Heavily Treated HIV PatientsPublished: March 7th 2024 | Updated:
Lenacapavir Reduces HIV Infections by 96%, Demonstrates Superiority Over Another HIV ProphylacticPublished: September 12th 2024 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Practically Expanding AI's role in Infectious Diseases
2
Maternal and Infant RSV Immunization Safe, Boosts Antibody Levels Regardless of Sequence
3
ID Week Brings Education, Networking and Conference Events Altogether Into One Conference
4
HIV Providers: Shortages and Uneven Distribution Across the US
5
